{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:20:36Z","timestamp":1791778836721,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.clml.2011.03.029","type":"journal-article","created":{"date-parts":[[2011,6,13]],"date-time":"2011-06-13T22:08:17Z","timestamp":1308002897000},"page":"S87-S90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"S1","title":["Non-Hodgkin's Lymphoma: The Old and the New"],"prefix":"10.1016","volume":"11","author":[{"given":"Fernando","family":"Cabanillas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.03.029_bib1","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.03.029_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2011.03.029_bib3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.029_bib4","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.029_bib5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.029_bib6","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008"},{"key":"10.1016\/j.clml.2011.03.029_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1358\/dot.2007.43.9.1112980","article-title":"Vorinostat in cutaneous T-cell lymphoma","volume":"43","author":"Duvic","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.clml.2011.03.029_bib8","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.029_bib9","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.029_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1358\/dof.2007.032.04.1094476","article-title":"Panobinostat","volume":"32","author":"Revill","year":"2007","journal-title":"Drugs of the Future"},{"key":"10.1016\/j.clml.2011.03.029_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2009.07837.x","article-title":"Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma","volume":"147","author":"Dickinson","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.03.029_bib12","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1158\/0008-5472.CAN-03-0799","article-title":"Histone deacetylase is a target of valproic acid-mediated cellular differentiation","volume":"64","author":"Gurvich","year":"2004","journal-title":"Cancer Res"},{"issue":"abstr","key":"10.1016\/j.clml.2011.03.029_bib13","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood.V114.22.1720.1720","article-title":"Valproic acid selectively inhibits STAT3 phosphorylation","volume":"114","author":"Zhu","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.029_bib14","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP-An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4 year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.029_bib15","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.029_bib16","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1080\/10428190701344907","article-title":"Valproic acid monotherapy leads to CR in a patient with refractory diffuse large B cell lymphoma","volume":"48","author":"Zain","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.03.029_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2119\/2007-00084.Bokelmann","article-title":"Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins","volume":"14","author":"Bokelmann","year":"2008","journal-title":"Mol Med"},{"key":"10.1016\/j.clml.2011.03.029_bib18","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/leu.2009.176","article-title":"Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis","volume":"23","author":"Stamatopoulos","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.03.029_bib19","doi-asserted-by":"crossref","unstructured":"P. Ganesan VR, R. Kumar. A phase II pilot study of valproic acid in relapsed\/refractory chronic lymphocytic leukemia. ASCO Meeting 2009;Abstract 7081.","DOI":"10.1200\/jco.2009.27.15_suppl.7081"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:21:53Z","timestamp":1761870113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011000437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":19,"alternative-id":["S2152265011000437"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.029","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-Hodgkin's Lymphoma: The Old and the New","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}